References
Tapia-Galisteo A, Álvarez-Vallina L, Sanz L (2023) Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies. J Hematol Oncol 16(1):83. https://doi.org/10.1186/s13045-023-01482-w
Shouse G (2023) Update on bi-specific monoclonal antibodies for blood cancers. Curr Opin Oncol 35(5):441–445. https://doi.org/10.1097/cco.0000000000000966
Olszewski AJ, Phillips TJ, Hoffmann MS, Armand P, Kim TM, Yoon DH, Mehta A, Greil R, Westin JR, Lossos IS, Munoz J, Sit J, Wei MC, Yang A, Chen V, Purev E, Yee DL, Jaeger U (2023) Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study. Blood Adv. https://doi.org/10.1182/bloodadvances.2023010840
Lynch RC, Poh C, Shadman M, Till BG, Smith SD, Ujjani C, Ottemiller S, Verni K, Fessel M, Joy B, Gausman D, Rasmussen H, Vandermeer J, Voutsinas J, Gopal AK (2023) Response-adapted mosunetuzumab for untreated follicular and marginal zone lymphomas: significant monotherapy activity seen in results of an interim efficacy analysis. Hematol Oncol 41(S2):577–578. https://doi.org/10.1002/hon.3164_432
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical approval
Treatment was approved by the Institutional Review Board. All procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.
Consent to particicpate
Patient provided written informed consent for case presentation.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Lucijanic, M., Sabljic, A., Vlasac Glasnovic, J. et al. Heavily pretreated patient with nodal marginal zone lymphoma successfully treated with mosunetuzumab. Ann Hematol 103, 1015–1016 (2024). https://doi.org/10.1007/s00277-023-05565-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-023-05565-z